10-Q: Dentsply Sirona Reports Mixed Q2 Results Amidst Restructuring Efforts

Dentsply Sirona's second-quarter results show a net loss, impacted by restructuring costs and market pressures, despite some growth in specific segments.

Summary

• Dentsply Sirona reported a net loss of $4 million for the second quarter of 2024, compared to a net income of $86 million in the same period last year.
• Net sales decreased by 4.2% to $984 million in Q2 2024, with a 2.3% decrease on an organic basis.
• The company's gross profit margin declined to 51.9% from 53.5% year-over-year.
• Operating expenses saw a decrease in selling, general, and administrative expenses, but restructuring costs increased significantly.
• The company is implementing a new restructuring plan expected to incur $40 to $50 million in charges and aims for $80 to $100 million in annual cost savings.
• The company repurchased approximately 5.4 million shares of common stock for $150 million during the quarter.
• The company has $1.29 billion remaining under its share repurchase program.
• The company's operations in Israel have not been materially impacted by the conflict, but sales of products made in Israel and sold in Turkey represent less than 2% of global sales of Implants & Prosthetics.
• The company's operations in Russia and Ukraine have not been materially impacted by the conflict, but net assets in these countries were $76 million, including $44 million of cash held in Russia.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with a net loss and declining sales, but also highlights cost-saving measures and growth in specific segments. The overall tone is cautious due to the ongoing restructuring and market challenges.

Positives

• Wellspect Healthcare segment showed strong organic sales growth of 11.7% in Q2 2024.
• Orthodontic and Implant Solutions segment also experienced positive organic sales growth of 4.6%.
• The company has substantially met its $200 million cost savings target from the 2023 restructuring plan.
• The company has $1.29 billion remaining under its share repurchase program.
• The company's days sales outstanding in accounts receivable decreased by 7 days to 52 days as compared to 59 days at December 31, 2023.

Negatives

• The Connected Technology Solutions segment experienced a significant organic sales decrease of 16.2% in Q2 2024.
• The company reported a net loss of $4 million for the quarter.
• Gross profit margin declined to 51.9% from 53.5% year-over-year.
• The company is facing competitive pricing pressures, particularly in imaging products.
• The company is experiencing weaker demand for equipment in Europe, particularly in Germany.
• The company is facing legislative changes impacting sales of direct-to-consumer aligners.

Risks

• The company faces risks related to the ongoing conflicts in Israel and Ukraine, which could impact operations and sales.
• The company is exposed to macroeconomic pressures, including inflation and higher interest rates, which could negatively impact demand.
• The company's distribution agreement with Patterson Companies is not being renewed, which could affect future sales.
• The company is subject to ongoing legal proceedings, including securities class action lawsuits, which could result in significant damages.
• The company faces potential impairment charges if market conditions worsen or key assumptions decline.
• The company is subject to potential tax liabilities related to an internal reorganization completed in 2016.

Future Outlook

The company expects continued inflationary pressure on raw materials and wages through the remainder of 2024. The company anticipates that the 2024 Plan will be substantially completed by the end of 2025 and result in $80 to $100 million in annual cost savings. The company intends to repurchase $100 million of shares in the third quarter of 2024, subject to market conditions.

Management Comments

• The 2023 Plans annual cost savings target of $200 million has been substantially met as of June 30, 2024, with the benefits mostly offset in the short term by additional investments in sales personnel, our new global ERP system, and other transformation initiatives.
• The Company expects to continue to maintain a level of investment in R&D that is at least 4% of annual net sales.

Industry Context

The dental industry is experiencing varying degrees of recessionary pressures, higher inflation, and supply chain constraints. Dentsply Sirona is facing increased competition and pricing pressures, particularly in the imaging equipment sector. The company is also navigating regulatory changes impacting its direct-to-consumer aligner business.

Comparison to Industry Standards

• Dentsply Sirona's revenue decline of 4.2% is worse than some of its competitors in the dental equipment and consumables market, such as Straumann which reported a 1.8% organic growth in the first half of 2024.
• The company's gross profit margin of 51.9% is lower than some of its peers, such as Align Technology which reported a gross margin of 70.8% in Q2 2024, indicating potential inefficiencies in manufacturing or pricing strategies.
• The company's restructuring efforts are similar to those of other large medical device companies seeking to streamline operations and reduce costs in response to economic pressures, such as Medtronic's recent restructuring announcement.
• The company's share repurchase program is a common strategy among large public companies to return value to shareholders, but the timing and amount of repurchases can vary significantly based on market conditions and company-specific factors.

Corporate Governance

Legal Proceedings

• The company is involved in several legal proceedings, including a putative class action related to the 2016 merger and another class action alleging false and misleading statements regarding revenue recognition.
• The company is also cooperating with the SEC regarding an internal investigation.
• A shareholder derivative suit has been filed in the Delaware Court of Chancery.
• The company is involved in a claim in the Milan Chamber of Arbitration related to a Share Purchase Agreement.

Stakeholder Impact

• Shareholders are impacted by the net loss and declining sales, but also by the share repurchase program.
• Employees are affected by the restructuring plans, which include workforce reductions.
• Customers may experience changes in product availability and pricing due to supply chain issues and competitive pressures.
• Suppliers may be impacted by the company's strategic procurement initiatives and cost-containment measures.

Next Steps

• The company will continue to implement the 2024 restructuring plan, aiming for $80 to $100 million in annual cost savings.
• The company intends to repurchase $100 million of shares in the third quarter of 2024, subject to market conditions.
• The company will engage in discussions for new distribution agreements with Patterson Companies.
• The company will continue to monitor and respond to legislative changes impacting its direct-to-consumer aligner business.

Key Dates

Keywords

Dentsply Sirona, dental equipment, dental consumables, restructuring, net loss, sales decline, gross profit, share repurchase, legal proceedings, market conditions, implants, orthodontics, CAD/CAM, Wellspect Healthcare, imaging equipment